Carlos M. Barrera

ORCID: 0000-0003-0628-4916
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Orthopedic Surgery and Rehabilitation
  • Shoulder Injury and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Respiratory and Cough-Related Research
  • Drug Transport and Resistance Mechanisms
  • Total Knee Arthroplasty Outcomes
  • Advanced MRI Techniques and Applications
  • Knee injuries and reconstruction techniques
  • Pneumonia and Respiratory Infections
  • Particle Detector Development and Performance
  • Neuroscience and Neuropharmacology Research
  • Sports injuries and prevention
  • Macrophage Migration Inhibitory Factor
  • Pituitary Gland Disorders and Treatments
  • Elbow and Forearm Trauma Treatment
  • Orthopaedic implants and arthroplasty
  • Alzheimer's disease research and treatments
  • Adenosine and Purinergic Signaling
  • Medical Malpractice and Liability Issues
  • Opioid Use Disorder Treatment
  • Advanced Neuroimaging Techniques and Applications
  • Growth Hormone and Insulin-like Growth Factors
  • Bone Tumor Diagnosis and Treatments
  • Lanthanide and Transition Metal Complexes
  • Biochemical and Molecular Research

Baptist Hospital of Miami
2024

University of Miami
2014-2020

Jackson Memorial Hospital
2018-2020

University of Miami Health System
2018-2019

Cempra Pharmaceuticals (United States)
2015

Instituto Nacional de Salud
2004

Kaiser Foundation Hospital
2003

Boston University
2000

Tulane Medical Center
1988-1992

Tulane University
1988-1992

Menno V. Huisman Kenneth J. Rothman Miney Paquette Christine Teutsch Hans‐Christoph Diener and 95 more Sérgio Dubner Jonathan L. Halperin Chang Sheng Kristina Zint Amelie Elsaesser Dorothee B. Bartels Gregory Y.H. Lip Dzifa Wosornu Abban Nasser Abdul Mark Abelson Alan Ackermann Fran Adams Luthando Adams Pedro Adragão Walter Ageno Rajesh Aggarwal Sergio Agosti Javier A. Marin Francisco Aguilar Julio Alberto Aguilar Linares Luis Aguinaga Zia Ahmad Paul Ainsworth Kamal Al Ghalayini Saad Al Ismail Abdelfatah Alasfar Abdul Alawwa Raed Al-Dallow Lisa Alderson Dimitrios Alexopoulos Abdullah Ali Malik Ali Pareed Aliyar Tammam Al-Joundi Soufian Al Mahameed Hossein Almassi Khalid Almuti Mohamed Al-Obaidi Mohamed Al‐Shehri Ute Altmann Alvaro Rabelo Alves Ayham Al-Zoebi W. Amara Mathieu Amelot Nima Amjadi Fabrizio Ammirati Nabil Andrawis Denis Angoulvant Giorgio Annoni Gerardo Ansalone Sorin Alexandru Antonescu M. Kevin Ariani Juan Carlos Arias Sébastien Armero Rohit Arora Chander Arora William Ashcraft Muhammad Shakil Aslam Alfredo Astesiano Philippe Audouin Charles Augenbraun Şenay Aydın Rabih R. Azar Abul Azim Shahid Aziz Luciano Marcelo Backes Mirza Amir Baig Suchdeep Bains Asaad I. Bakbak Seth Baker Karim Bakhtiar Richard Bala Jonathan Banayan Stellan Bandh Shigenobu Bando Subhash Banerjee Alan J. Bank О. Л. Барбараш Gonzalo Barón‐Esquivias Craig Barr Carlos M. Barrera John R. Barton Vanja Bašić Kes Giovanni Baula Hamid el Bayeh Nooshin Bazargani Steffen Behrens Alan Bell Juan Benezet‐Mazuecos Bouziane Benhalima Philippe Berdagué Brian J. Berg van den P.F.M.M. Bergen van Edvard Berngard Richard A. Bernstein

GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns patients newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non–vitamin K antagonist oral anticoagulant (NOAC), became available. This study sought to describe phase baseline data and compare these pre-NOAC era collected during 1. During 2,...

10.1016/j.jacc.2016.11.061 article EN cc-by-nc-nd Journal of the American College of Cardiology 2017-02-01

The acute GH release stimulated by the synthetic hexapeptide, His-DTrp-Ala-Trp-DPhe-Lys-NH2 [GH releasing peptide (GHRP)], was determined in 18 normal men and compared with effects of GH-releasing hormone, GHRH-(1–44)-NH2. Specificity effect assessed measurement serum PRL, LH, TSH, cortisol. GHRP administered at doses 0.1, 0.3, 1.0 μg/kg iv bolus. GHRH a dose alone together various does GHRP. No adverse clinical or laboratory abnormalities were observed response to A side-effect mild facial...

10.1210/jcem-70-4-975 article EN The Journal of Clinical Endocrinology & Metabolism 1990-04-01

Analogs of somatostatin are being investigated clinically for the treatment various malignancies, including brain tumors. We studied ability three therapeutically promising radioactively labeled octapeptide analogs, RC-160, RC-121, and RC-161, to cross blood-brain barrier (BBB) after peripheral or central injection. After i.v. injection, intact RC-160 was recovered from blood brain. The entry rates were different each compound but generally low. By contrast, across BBB increased 220 times...

10.1073/pnas.87.17.6762 article EN Proceedings of the National Academy of Sciences 1990-09-01

Systemic administration of luteinizing hormone-releasing hormone (LHRH) in rats has been found to influence behavior independently pituitary or ovarian function. A previous study shown that LHRH can cross the blood-brain barrier one direction, but it was not known whether this due a saturable transport system. The rate entry 125I-labeled from blood brain determined by two different single-pass methods carotid perfusion. first, multiple time point method, measures Ki slope linear regression...

10.1152/ajpendo.1991.261.3.e312 article EN AJP Endocrinology and Metabolism 1991-09-01

10.1016/j.jmbbm.2016.09.029 article EN Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials 2016-09-24

Quadriceps tendon (QT)-bone autografts used during anterior cruciate ligament (ACL) reconstruction have provided comparable outcomes and decreased donor-site morbidity when compared with bone-patellar tendon-bone (BPTB) autografts. No study has directly the of all-soft tissue QT autograft that BPTB autograft.Patient-reported knee outcome scores rates postoperative complication after primary ACL are no different from at a minimum 2-year follow-up.Cohort study; Level evidence, 3.A total 75...

10.1177/2325967119890063 article EN cc-by-nc-nd Orthopaedic Journal of Sports Medicine 2019-12-01

ABSTRACT The host-encoded Perforin-2 (encoded by the macrophage-expressed gene 1, Mpeg1 ), which possesses a pore-forming MACPF domain, reduces viability of bacterial pathogens that reside within membrane-bound compartments. Here, it is shown also restricts proliferation intracytosolic pathogen Listeria monocytogenes . Within few hours systemic infection, massive L. in Perforin -2 −/− mice leads to rapid appearance acute disease symptoms. We go on show cultured cells vacuole-to-cytosol...

10.1128/iai.01434-15 article EN Infection and Immunity 2016-02-02

10.1016/0361-9230(89)90186-x article EN Brain Research Bulletin 1989-12-01

10.1016/0091-3057(89)90515-7 article EN Pharmacology Biochemistry and Behavior 1989-06-01

Objective To evaluate changes in knee articular cartilage of novice half-marathon runners using magnetic resonance imaging T2 relaxation time mapping. Methods Healthy subjects were recruited from local running clubs who met the following inclusion criteria: (i) age 18–45 years; (ii) body mass index less than 30 kg/m 2 ; (iii) had participated one or (none within previous 6 months); (iv) run 20 km/week; (v) no injury surgery; (vi) pain. signals measured pre- and post-race to biochemical after...

10.1177/0300060519874140 article EN cc-by-nc Journal of International Medical Research 2019-09-30
Coming Soon ...